Overcoming IP Reconciliation Challenges in Direct-to-Patient (DTP) Clinical Trial Models
Overcoming IP Reconciliation Challenges in Direct-to-Patient (DTP) Clinical Trial Models Managing Investigational Product Reconciliation in DTP Clinical Trials As Decentralized Clinical Trials (DCTs) continue to evolve, Direct-to-Patient (DTP) drug delivery models offer unmatched convenience. However, they also introduce complexity in reconciling Investigational Product (IP) inventories. Ensuring accountability of all IP—dispensed, returned, lost, or consumed—is critical…